Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 37-48 of 212 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 37-48 of 212 studies
-
Anti-InflammatoryClosed to Enrollment
Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa , protocol number Calithera CX-280-202This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
2 months
-
-
Anti-InflammatoryClosed to Enrollment
Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-002This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Anti-InflammatoryClosed to Enrollment
Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
6
-
Length of Participation:
189 days
-
-
Anti-InflammatoryClosed to Enrollment
Phase 2 study of GS-5745 in adults with CF , protocol number Gilead GS-US-404-1808This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the anti-inflammatory drug GS-5745 and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 80%
-
Number of Visits:
6
-
Length of Participation:
24 weeks
-
-
Anti-InfectiveClosed to Enrollment
Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a) , protocol number BiomX BMX-04-001 Part 2This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
192 days
-
-
Anti-InfectiveClosed to Enrollment
Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a) , protocol number BiomX BMX-04-001 Part 1This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
7
-
Length of Participation:
189 days
-
-
Anti-InfectiveClosed to Enrollment
Study of Lefamulin in Adults with CF , protocol number Nabriva NAB-BC-3781-1014This study will look at the safety and how the body processes lefamulin, a drug intended to treat infections in the lung. This study is for adults with CF.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
13 days
-
-
Anti-InfectiveClosed to Enrollment
Study to evaluate inhaled AR-501 in healthy adults and adults with cystic fibrosis and Pseudomonas aeruginosa , protocol number Aridis AR-501-001 MAD cohortsThis study is testing inhaled AR-501, a drug intended to treat infections in the lung. The study will measure the drug’s safety, how well it works, and how the body processes it. Multiple doses of AR-501 will be tested in both healthy adults and adults with cystic fibrosis who are infected with Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
45% or greater
-
Number of Visits:
11
-
Length of Participation:
6 weeks
-
-
Anti-InfectiveClosed to Enrollment
STOP-PEDS Pilot: Study to evaluate treatment of pulmonary exacerbations in children 6-18 years old with CF , protocol number STOP-PEDS PilotThis study will evaluate children 6 to 18 years old with CF to determine the acceptability and feasibility of a larger trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation treatment.
-
Age:
6 Years to 18 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50% or greater
-
Number of Visits:
3
-
Length of Participation:
18 months
-
-
Anti-InfectiveClosed to Enrollment
Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 MAD) , protocol number Armata AP-PA02-101 MADThis study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
38 days
-
-
Anti-InfectiveClosed to Enrollment
Study to evaluate inhaled AP-PA02 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Armata Phase 1b/2 SAD) , protocol number Armata AP-PA02-101 - SADThis study will look at the safety and tolerability of inhaled AP-PA02, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
60% or greater
-
Number of Visits:
8
-
Length of Participation:
29 days
-
-
Anti-InfectiveClosed to Enrollment
Phase 2 study of inhaled nitric oxide in people with CF , protocol number Novoteris NO-CF-02EThis study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
35 to 85%
-
Number of Visits:
10
-
Length of Participation:
43 days
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More